Showing 101 - 120 results of 499 for search 'Real option evaluation', query time: 0.13s Refine Results
  1. 101

    The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: a single center real-world retrospective study by Yanzhen Yang, Yanzhen Yang, Qu Xie, Qu Xie, Chuankai Shang, Chuankai Shang, Lai Jiang, Guojun Ding, Dan Long, Cong Luo

    Published 2025-05-01
    “…This single-center, retrospective study evaluates the potential efficacy of combination therapy containing Surufatinib in advanced or metastatic pancreatic cancer.MethodWe conducted a real world retrospective study of mPDAC patients who received the Surufatinib between July 2022 and July 2023 at Zhejiang Cancer Hospital. …”
    Get full text
    Article
  2. 102
  3. 103
  4. 104

    Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments by Abouch Krymchantowski, Carla Jevoux, Élcio Juliato Piovesan, Marcelo Moraes Valença, Fernando Kowacs, Pedro André Kowacs, Fabíola Dach, Paulo Hélio Monzillo, Carlos Alberto Bordini, Raimundo Pereira Silva-Néto

    Published 2024-12-01
    “…Abstract Objective To present the first Brazilian real-world results with galcanezumab and provide a consensus expert opinion on the prophylactic treatment of cluster headache (CH) in Brazil. …”
    Get full text
    Article
  5. 105

    Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China by Guangming Tian, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiangjuan Ma, Xiaoling Chen, Sen Han, Jindi Han, Ziran Zhang, Jieran Long, Xinliang Zhao, Jian Fang

    Published 2025-05-01
    “…This study evaluates the real-world efficacy and safety of lorlatinib in Chinese patients with advanced ALK-positive NSCLC.Materials and methodsThis retrospective study analyzed 65 patients with advanced ALK-positive NSCLC who received lorlatinib at Peking University Cancer Hospital between September 2017 and August 2024. …”
    Get full text
    Article
  6. 106
  7. 107
  8. 108
  9. 109

    Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand by Sirapat Korwiwattanakan, Surangkana Samanloh, Pinyo Rattanaumpawan

    Published 2025-08-01
    “…Background: Nirmatrelvir/ritonavir, remdesivir, and molnupiravir are recommended antiviral therapies for non-severe COVID-19 patients at high risk of disease progression. This study evaluated the real-world effectiveness and economic impact of these three antiviral regimens in Thailand. …”
    Get full text
    Article
  10. 110
  11. 111

    Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer by Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova

    Published 2021-10-01
    “…Objective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. …”
    Get full text
    Article
  12. 112
  13. 113

    Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients by Ye Ji Kim, Youn Gon Lee, Dong Won Lee, Jae Hui Kim

    Published 2018-01-01
    “…Purpose. To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). …”
    Get full text
    Article
  14. 114

    Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study by Josselin Annic, Hélène Babey, Romain Corre, Renaud Descourt, Gilles Quéré, Emmanuelle Renaud, Mickaël Lambert, Pierre Le Noac'h, Estelle Dhamelincourt, Jessica Nguyen, Alicia Vu, Vincent Bourbonne, Gilles Robinet, Margaux Geier

    Published 2023-02-01
    “…Methods EpiTax is a retrospective multicenter observational real‐life study. We evaluated the efficacy of epirubicin 90 mg/m2 combined with paclitaxel 175 mg/m2 every 3 weeks in SCLC patients after failure of at least one line of platinum‐based chemotherapy. …”
    Get full text
    Article
  15. 115

    Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study) by N. A. Demidov, M. B. Antsiferov, A. V. Zilov

    Published 2021-02-01
    “…It seems important to study this treatment option also in real clinical practice.AIMS: To evaluate the effectiveness and safety of the initiation with Galvus Met® as compared with any other combination therapy approaches used in everyday clinical practice.MATERIALS AND METHODS: multicenter prospective observational study in 15 regions of Russia lasting 6 months. …”
    Get full text
    Article
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120